Final analysis of European patients from the Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) study: Baseline characteristics and staging systems.

Bruno Daniele,Vlad Ratziu,Per Stål,Fátima Serejo,Gyorgy Bodoky,Adina E Croitoru,Christos N. Papandreou,Juan Turnes,Marc Mardoche Fellous,Philippe Mathurin,Jean-Pierre Bronowicki

Final analysis of European patients from the Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) study: Baseline characteristics and staging systems.

2014

Bruno Daniele
Vlad Ratziu
Per Stål
Fátima Serejo
Gyorgy Bodoky
Adina E Croitoru
Christos N. Papandreou
Juan Turnes
Marc Mardoche Fellous
Philippe Mathurin
Jean-Pierre Bronowicki

4088 Background: The global, prospective, non-interventional GIDEON study recruiting >3,000 patients with unresectable hepatocellular carcinoma treated with sorafenib is complete. We report the fin...

Keywords:

Hepatocellular carcinoma
Pathology
Sorafenib
Medicine
baseline characteristics
Internal medicine
Oncology
Stage (cooking)
Physical therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations